Danish pharmaceutical giant Novo Nordisk was hit with a class action lawsuit in New York federal court on Friday for allegedly misusing its patents to maintain a monopoly on its diabetes drug Victoza.

Smith ⁠Drug asked the court for an unspecified amount of monetary damages on behalf of a proposed class of Victoza purchasers ...

Novo Nordisk faces a class action lawsuit for allegedly monopolizing its diabetes drug Victoza through patent misuse and ...

Novo Nordisk (NVO) faces a class action suit over claims it ran a pay-for-delay deal with Teva (TEVA) to delay generics for its diabetes drug Victoza. Read more here.

By Maggie Fick and Michael Erman SAN FRANCISCO, Jan 26 (Reuters) - Artificial intelligence has yet to deliver on the most ...

On its fourth-quarter earnings conference call on Jan. 21, Johnson & Johnson JNJ announced its financial outlook for 2026, ...

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. , today announced a partnership with actor, comedian and advocate, Will Forte, to increase awareness of Huntington's ...

Boehringer Ingelheim has added another drug to its immunology pipeline, licensing an inflammatory bowel disease (IBD) ...

The cash injection will also allow Corxel to start phase 2 testing in type 2 diabetes and help to fund a phase 3 programme in ...

As Sandoz looks to address the “biosimilar void” created by the scores of lucrative drugs going off patent in the next decade ...